Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Fayoum, Egypt
Abdelrazik, A., Sauza, R., Abdelaziz, H. (2023). Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Fayoum, Egypt. EKB Journal Management System, 4(1), 32-42. doi: 10.21608/ejmr.2023.166111.1274
Abeer Mohamed Abdelrazik; Rhogenie Baselly Sauza; Hossam M. Abdelaziz. "Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Fayoum, Egypt". EKB Journal Management System, 4, 1, 2023, 32-42. doi: 10.21608/ejmr.2023.166111.1274
Abdelrazik, A., Sauza, R., Abdelaziz, H. (2023). 'Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Fayoum, Egypt', EKB Journal Management System, 4(1), pp. 32-42. doi: 10.21608/ejmr.2023.166111.1274
Abdelrazik, A., Sauza, R., Abdelaziz, H. Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Fayoum, Egypt. EKB Journal Management System, 2023; 4(1): 32-42. doi: 10.21608/ejmr.2023.166111.1274

Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Fayoum, Egypt

Egyptian Journal of Medical Research
Volume 4, Issue 1, January 2023, Page 32-42  XML PDF (330.8 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2023.166111.1274
View on SCiNiTO View on SCiNiTO
Authors
Abeer Mohamed Abdelrazik email orcid 1; Rhogenie Baselly Sauza2; Hossam M. Abdelaziz1
1Clinical Pathology Department, Faculty of Medicine, Fayoum University, Egypt.
2Medical Laboratory Technologist, Yas clinic Group
Abstract
Background: More eligibility criteria have been added for blood donors to warrant safety of blood donations during the COVID-19 pandemic. The aim of this study was to assess the seroprevalence of antibodies to SARS-CoV-2 among blood donors and to study the lifestyle of asymptomatic cases.Methods: One thousand, three hundred twelve voluntary blood donors were enlisted in this study in the University Hospital from September to December 2021. Samples were tested for SARS-CoV-2 antibody. Donor’s lifestyle was analyzed.  Results: 95.4% of the studied group were males, the seroprevalence of SARS-CoV-2 antibody was 83.3% and related to gender, regular donation, type of donation, and more frequent when donors shared transport and accommodation. 9.5% were found to possess cough/fever or a history of contact with COVID-19 patients.  Conclusion: Blood donors proved to give an idea about virus spreading among healthy population.  Additional risk factors can be identified to ensure safety of transfusion.
Keywords
SARS-CoV-2 antibody; eligibility criteria; blood donors
References
  1. She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med. 2020 Feb 20;9(1):19. doi: 10.1186/s40169-020-00271-z. PMID: 32078069; PMCID: PMC7033263.
  2. Marte Hvalryg, Lise Sofie H. Nissen-Meyer, Sero-prevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Norway, winter/spring 2021, Transfusion and Apheresis Science, Volume 60, Issue 5, 2021, 103256, ISSN 1473-0502.
  3. Girgis, S.A., Hafez, H.M., Elarab, H.E., Sherif, B., Sabry, M.H., Afifi, I., Hassan, F.E., Reda, A., Elsayed, S., Mahmoud, A., Habeb, P., Habil, I.S., Hussein, R.S., Mossad, I.M., Mansour, O., Omar, A., Saleh, A.M., El-Meteini, M., 2021. SARS-CoV-2 PCR positivity rate and seroprevalence of related antibodies among a sample of patients in Cairo: Pre-wave 2 results of a screening program in a university hospital. Plos One, https://doi.org/10.1371/journal.pone.0254581.
  4. Roser, M., Ritchie, H., Ortiz-Ospina, E. and Hasell, J., 2020. Coronavirus pandemic (COVID-19). Our world in data, 4.
  5. Ma Q, Liu J, Liu Q, et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals with Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4(12):e2137257. doi:10.1001/jamanetworkopen.2021.37257
  6. Stone M, Di Germanio C, Wright DJ, Sulaeman H, Dave H, Fink RV, Notari EP, Green V, Strauss D, Kessler D, Destree M, Saa P, Williamson PC, Simmons G, Stramer SL, Opsomer J, Jones JM, Kleinman S, Busch MP; NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P). Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program. Clin Infect Dis. 2022 Mar 9;74(5):871-881. doi: 10.1093/cid/ciab537. PMID: 34111244; PMCID: PMC8406874.
  7. Sebastião, C.S., Galangue, M., Gaston, C. et al. Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola. BMC Infect Dis 21, 1131 (2021). https://doi.org/10.1186/s12879-021-06814-0.
  8. Filho LA, Szwarcwald CL, Mateos S de OG, de Leon ACMP, de Andrade Medronho R, Veloso VG, et al. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil. Rev Saude Publica. 2020; 54:1–10.
  9. Sridhar D., Gurdasani D. Herd immunity by infection is not an option. Science. 2021; 371:230–231. doi: 10.1126/science.abf7921.
  10. Raouf M, Rabeh M, Kaur S, Sharma R, Thottumkal N, Mohammed R: Seroprevalence of IgG AntiSARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors. Dubai Med J 2021; 4:204-211. doi: 10.1159/000517456.
  11. World Health Organization. Guidance on maintaining a safe and adequate blood supply during the coronavirus disease 2019 (COVID-19) pandemic and on the collection of COVID-19 convalescentplasma.WHO;2020Jul10.
  12. Garg S, Singh MM, Deshmukh CP, Bhatnagar N, Borle AL, Kumar R. Critical interpretative synthesis of herd immunity for COVID-19 pandemic. J Family Med Prim Care. 2021 Mar;10(3):1117-1123. doi: 10.4103/jfmpc.jfmpc_1127_20. Epub 2021 Apr 8. PMID: 34041138; PMCID: PMC8140252.
  13. Coronavirus (COVID-19) Update: Serological Tests | FDA [Internet]. [cited 2021 Jan 4]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-updateserological-tests.
  14. Eldesoukey, N, Gaafar, T, Enein, AA, et al. SARS-CoV-2 antibody seroprevalence rates among Egyptian blood donors around the third wave: cross-sectional study. Health Sci Rep. 2022; 5:e634. doi:10.1002/hsr2.634.
  15. Vahidy FS, Pan AP, Ahnstedt H, Munshi Y, Choi HA, Tiruneh Y, et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: cross-sectional analysis from a diverse US metropolitan area. PLoS One. 2021;16(1): e0245556.
  16. Slot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat JHM, et al. Low SARSCoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. Nat Commun. 2020; 11:5744.
  17. Dodd RY, Xu M, Stramer SL. Change in donor characteristics and antibodies to SARS-CoV-2 in donated blood in the US, June–August 2020. JAMA. 2020;324(16):1677–9.
  18. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science. 2021;371(6524):79–82.
  19. Heydar Ali Balou, Tofigh Yaghubi Kalurazi, Farahnaz Joukar, Soheil Hassanipour, Mohammad Shenagari, Mahmoud Khoshsorour, Fariborz Mansour-Ghanaei, "High Seroprevalence of SARSCoV-2 (COVID-19)-Specific Antibodies among Healthcare Workers: A Cross-Sectional Study in Guilan, Iran", Journal of Environmental and Public Health, vol. 2021, Article ID 9081491, 8 pages, 2021. https://doi.org/10.1155/2021/9081491
  20. -B. Wu, D.-Z. Gu, J.-N. Yu, J. Yang, and W.-Q. Shen, “Association between ABO blood groups and COVID-19 infection, severity and demise: a systematic review and meta-analysis,” Infection, Genetics and Evolution, vol. 84, Article ID 104485, 2020.
  21. Lundkvist A, Hanson S, Olsen B. Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Stockholm, Sweden. Infect Ecol Epidemiology. 2020; 10:1.
Statistics
Article View: 282
PDF Download: 170